托珠单抗治疗新型冠状病毒肺炎。回复。 - Suppr

Suppr

超能文献

Tocilizumab in Covid-19. Reply.

作者信息

Stone John H, Horick Nora K, Healy Brian C

机构信息

Massachusetts General Hospital, Boston, MA

出版信息

N Engl J Med. 2021 Jan 7;384(1):87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

DOI:10.1056/NEJMc2032911

PMID:33356050

Abstract

摘要

相似文献

Tocilizumab in Covid-19. Reply.

N Engl J Med. 2021 Jan 7;384(1):87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

Tocilizumab in Covid-19.

N Engl J Med. 2021 Jan 7;384(1):86-87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.

Transpl Infect Dis. 2020 Aug;22(4):e13326. doi: 10.1111/tid.13326. Epub 2020 Jun 5.

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.

Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.

Lack of tocilizumab effect on mortality in COVID19 patients.

Sci Rep. 2020 Oct 13;10(1):17100. doi: 10.1038/s41598-020-74328-x.

Cytokine Storm Drugs Move from CAR T to COVID-19.

Cancer Discov. 2020 Jul;10(7):OF8. doi: 10.1158/2159-8290.CD-ND2020-008. Epub 2020 May 5.

Covid-19 controversies: the tocilizumab chapter.

BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.

Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?

Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):e81-e82. doi: 10.1093/ehjcvp/pvab051.

Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients.

Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):30898-30899. doi: 10.1073/pnas.2017204117. Epub 2020 Nov 17.

Tocilizumab for COVID-19: a real 'miracle drug'?

Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.

引用本文的文献

Pharmacological treatment of COVID-19: an opinion paper.

Rev Esp Quimioter. 2022 Apr;35(2):115-130. doi: 10.37201/req/158.2021. Epub 2021 Dec 11.

Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study).

Infect Dis Ther. 2021 Dec;10(4):2735-2748. doi: 10.1007/s40121-021-00543-2. Epub 2021 Oct 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Tocilizumab in Covid-19. Reply.

N Engl J Med. 2021 Jan 7;384(1):87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

Tocilizumab in Covid-19.

N Engl J Med. 2021 Jan 7;384(1):86-87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.

Transpl Infect Dis. 2020 Aug;22(4):e13326. doi: 10.1111/tid.13326. Epub 2020 Jun 5.

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.

Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.

Lack of tocilizumab effect on mortality in COVID19 patients.

Sci Rep. 2020 Oct 13;10(1):17100. doi: 10.1038/s41598-020-74328-x.

Cytokine Storm Drugs Move from CAR T to COVID-19.

Cancer Discov. 2020 Jul;10(7):OF8. doi: 10.1158/2159-8290.CD-ND2020-008. Epub 2020 May 5.

Covid-19 controversies: the tocilizumab chapter.

BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.

Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?

Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):e81-e82. doi: 10.1093/ehjcvp/pvab051.

Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients.

Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):30898-30899. doi: 10.1073/pnas.2017204117. Epub 2020 Nov 17.

Tocilizumab for COVID-19: a real 'miracle drug'?

Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.

引用本文的文献

Pharmacological treatment of COVID-19: an opinion paper.

Rev Esp Quimioter. 2022 Apr;35(2):115-130. doi: 10.37201/req/158.2021. Epub 2021 Dec 11.

Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study).

Infect Dis Ther. 2021 Dec;10(4):2735-2748. doi: 10.1007/s40121-021-00543-2. Epub 2021 Oct 17.